Viral vaccines containing infectious agents can be developed by classical techniques. Viral vaccines prevent or modify the severity of illness in the individual and interrupt or reduce the transmission of the pathogens to other susceptible people.
Cell Culture Rabies Vaccine (CCRV)
The vaccine is a liquid preparation of rabies fixed virus grown in vero cells. After incubation and harvest, the virus suspension is inactivated, concentrated and purified to which a stabilizer is added. It is a whitish clear liquid containing Thimerosal as a preservative. Each vial contains 0.5ml volume having 2.5 I.U. purified and inactivated rabies virus. This vaccine meets WHO requirements for rabies pre and post-exposure prophylaxis.
Measles Vaccine
About Product:
Measles vaccine is the active immunizing agent for the prevention of measles. Measles Virus Vaccine, Live, Attenuated (Dried) is prepared in avian leukosis-free chick embryo fibroblast cultures from the connaught strain, a strain of measles virus derived from the same original isolate as were other vaccine strains, such as Schwarz. The connaught strain was attenuated by sixty-nine passages in chick embryo fibroblast cultures.
The vaccine is freeze-dried in multiple-dose vials. Each dose contains not less than 1000 TCID of measles virus and not more than 10 mcg streptomycin and not more than 0.5 mcg neomycin. The vaccine fulfills the WHO Requirements for Measles Vaccine (Live).
How to use
- According to the labeled amount, add attached sterile water for injection with vaccine, shake the vaccine to use after dissolution.
- A single dose of 0.5 ml should be administered by subcutaneous injection into the lower edge of the outer deltoid.
Leaflet PDF:
https://drive.google.com/file/d/1MKDIKF-f5F37-DkjCb_Zwn0onP3IZwCu/view?usp=sharing
PakVac
PakVac vaccine is Ad5-nCoV recombinant vaccine which is being manufactured at NIH with the help of Cansino bio from China. This joint venture began when NIH and a local pharma company AJM pharma joined hands with the Cansino bio to launch the phase III clinical trials of this vaccine in late 2020. The CanSino vaccine operates by injecting antibodies that the immune system then uses to protect against further invasions. The vaccine provides maximum protection after two shots.
Leaflet:
https://drive.google.com/file/d/1DjrNPCS-K-gJdreQDQn4f_dITExFBsjS/view?usp=sharing
